Vertex (VRTX) Slumps on VX-809 Data Presentation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Analyst Says Vertex (VRTX) Drug Data Shows "At Least Moderate Impact"
October 12, 2012 8:29 AM EDTVertex Pharmaceuticals (Nasdaq: VRTX) presented additional data from cohort 2 of the Phase 2 VX-809 (lumacaftor/ivacaftor) trial in F508del cystic fibrosis patients at the NACFC meeting yesterday.
Commenting on the data, analyst Alan Carr of Needham and Company said "Although interpretation... More
